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Abstract
Background: Metabolic syndrome is a cluster of common cardiovascular risk factors that includes
hypertension and insulin resistance. Hypertension and diabetes mellitus are frequent comorbidities
and, like metabolic syndrome, increase the risk of cardiovascular events. Telmisartan, an
antihypertensive agent with evidence of partial peroxisome proliferator-activated receptor activity-
gamma (PPARγ ) activity, may improve insulin sensitivity and lipid profile in patients with metabolic
syndrome.
Methods:  In a double-blind, parallel-group, randomized study, patients with World Health
Organization criteria for metabolic syndrome received once-daily doses of telmisartan (80 mg, n =
20) or losartan (50 mg, n = 20) for 3 months. At baseline and end of treatment, fasting and
postprandial plasma glucose, insulin sensitivity, glycosylated haemoglobin (HBA1c) and 24-hour
mean systolic and diastolic blood pressures were determined.
Results: Telmisartan, but not losartan, significantly (p < 0.05) reduced free plasma glucose, free
plasma insulin, homeostasis model assessment of insulin resistance and HbAic. Following treatment,
plasma glucose and insulin were reduced during the oral glucose tolerance test by telmisartan, but
not by losartan. Telmisartan also significantly reduced 24-hour mean systolic blood pressure (p <
0.05) and diastolic blood pressure (p < 0.05) compared with losartan.
Conclusion: As well as providing superior 24-hour blood pressure control, telmisartan, unlike
losartan, displayed insulin-sensitizing activity, which may be explained by its partial PPARγ  activity.
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Background
Metabolic syndrome describes the presence of a cluster of
common cardiovascular risk factors, including hyperten-
sion, insulin resistance or glucose intolerance, visceral
obesity, atherogenic dyslipidemia, prothrombotic state
and proinflammatory state in a single individual [1,2].
The lack of a universally agreed definition has impeded
epidemiologic work on the prevalence and antecedents of
this syndrome. Nevertheless, it has been proposed that the
metabolic syndrome is present in about 10–25% of indi-
viduals in industrialized countries [3,4]. The increasing
availability and abundance of high-calorie, low-fiber
foods and the adoption of more sedentary lifestyles are
also leading to increased prevalence of the metabolic syn-
drome in developing countries [5]. Its presence predicts a
two- to four-fold increase in the risk of cardiovascular dis-
ease and death [6,7] and the risk of developing type 2 dia-
betes is increased five- to nine-fold [3,8].
In general, components of the metabolic syndrome are
treated individually, there being no current treatment that
targets all features. Some classes of antihypertensives,
notably calcium channel blockers, angiotensin-converting
enzyme (ACE) inhibitors and angiotensin II receptor
blockers (ARBs), have been shown to reduce the incidence
of new-onset diabetes, particularly when compared with
diuretics and β -blockers [9]. This suggests that antihyper-
tensive agents have differential effects on hyperglycemia
in patients with metabolic syndrome. However, there are
few data on intra-class differences. Recent in vitro and ani-
mal studies suggest that telmisartan, unlike other ARBs,
acts as a partial peroxisome proliferator-activated recep-
tor-gamma (PPARγ ) agonist at concentrations that are
achievable with oral doses recommended for the treat-
ment of hypertension, thus suggesting its insulin-sensitiz-
ing effect [10-12]
The aim of the present study was to compare the gluco-
metabolic effect of telmisartan and losartan, two ARBs
with potentially different effects on glycemia, in patients
with metabolic syndrome.
Materials and methods
The study population included men and women aged
between 18 and 75 years with arterial hypertension and
the diagnosis of metabolic syndrome. All subjects were
newly diagnosed as being hypertensive (office systolic
blood pressure [SBP] ≥  135 mmHg, diastolic blood pres-
sure [DBP] ≥  85 mmHg). Patients were required to have
insulin resistance, impaired glucose tolerance (IGT) or
type 2 diabetes, according to the diagnostic criteria for the
metabolic syndrome of the World Health Organization
[1]. Insulin resistance was defined as HOMA-IR > 3.5,
impaired glucose tolerance (IGT) was defined as 2-hour
values in the oral glucose tolerance test (OGTT) of ≥  140
mg/dl (≥  7.8 mmol/l), but <200 mg/dl (<11.1 mmol/l).
Diabetes was diagnosed as free plasma glucose (FPG) ≥
126 mg/dl (≥  7.0 mmol/l) or 2-hour post-glucose load of
≥  200 mg/dl (≥  11.1 mmol/l). Patients with hyperkalemia
or serum creatinine >2 mg/dl were excluded.
After evaluation of all inclusion and exclusion criteria, eli-
gible patients entered a randomized, parallel-group, dou-
ble-blind study. After a baseline 24-hour ambulatory
blood pressure monitoring and an OGTT, they were
assigned to the two treatment groups using equal weight-
ing and electronic randomization, and received either
once-daily telmisartan 80 mg or losartan 50 mg for 3
months. These dosages were employed because they are
the highest approved for the treatment of hypertension on
the basis of Italian licensing. Patients were asked to adhere
to their standard eating habits and physical activity
throughout the study.
Patients were assessed at baseline (first visit) and after 3
months' treatment. Fasting (minimum 12 hours) blood
samples (10 ml) were obtained for laboratory evaluation
of hematology and clinical chemistry parameters, includ-
ing total cholesterol, LDL cholesterol, high-density lipo-
protein (HDL) cholesterol, triglycerides, glucose and
insulin. An OGTT was conducted using 75 g glucose.
Blood samples (10 ml) were withdrawn at 30-minute
intervals over 120 minutes for determination of glucose
and insulin response. An autoanalyzer (Olympus) was
used to assay plasma glucose using the hexokinase
method, plasma triglycerides using the glycerol-3-phos-
phate oxidase-p-aminophenazone method; cholesterol
using cholesterol oxidase phenol ampyrone method; HDL
cholesterol using immunoinhibition; glycosylated hemo-
globin (HbA1c) with the Abbott AxSYM analyzer (Abbott
SpA Divisione Diagnostici, Rome, Italy) using microparti-
cle enzyme immunoassay; and free plasma insulin (FPI).
Insulin resistance was measured using the homeostasis
model assessment (HOMA-IR) [13], defined by the fol-
lowing formula:
Trough clinical blood pressures were recorded at baseline
and after treatment using cuff sphygmomanometry.
Ambulatory blood pressure monitoring (ABPM) was per-
formed with an oscillometric device (Tonoport V; GE
Medical Systems IT Inc., Milwakee, WI, USA) recom-
mended for clinical use and that had previously been val-
idated. The monitor was programmed to measure SBP
and DBP every 20 minutes between 06.00 and 22.59 (day-
time period) and every 30 minutes between 23.00 and
05.59 (night-time period). A standard, adult-sized arm
HOMA-IR =
fasting FPG (mmol/l) x fasting FPI (mU/ml)
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cuff (length 12 cm) was positioned in the middle of the
non-dominant arm covering the brachial artery above the
antecubital fossa. The correct position for the cuff was
confirmed when three SBP and DBP values were concord-
ant (within 5 mmHg) with those obtained from the oppo-
site arm with a standard sphygmomanometer. The arm
cuff was inflated automatically by a pump, and the blood
pressure was digitally recorded on the hard disk of a per-
sonal computer to which the device was connected.
Patients were instructed to continue their usual daily
activities, but to keep their arm still and parallel to the
trunk during ambulatory blood pressure measurements,
and to return to the hospital 24 hours after initiation of
the ABPM.
ABPM data were excluded from analysis if >30% of the
measurements were lacking, if data were missing for >3-
hour spans, or if collected from patients who were experi-
encing an irregular rest-activity schedule or a night-time
sleep span was <6 hours or >12 hours during ABPM. Mean
SBP and DBP values for the daytime (06.00–22.59) and
night-time (23.00-05.59) periods were calculated as mean
values of the hourly averages. Smoothness index was cal-
culated as the ratio of the standard deviation of the hourly
blood pressure value to the 24-hour mean [14].
Body mass index (BMI) was measured as the ratio of
weight (kg) to height (m2). Waist circumference was
measured with a tape measure placed horizontally around
Table 1: Patient baseline characteristics
Losartan (n = 20) Telmisartan (n = 20) P value
Mean ± SD age (years) 56.2 ± 11.0 55.3 ± 12.4 NS
Males/females 11/9 12/8
Office blood pressure (mmHg)
Mean ± SD SBP 149.7 ± 9.0 151.3 ± 7.1
Mean ± SD DBP 91.2 ± 7.4 89.8 ± 8.7
24-hour mean blood pressure (mmHg)
Mean ± SD SBP 142.8 ± 12.0 143.6 ± 14.0 NS
Mean ± SD DBP 88.8 ± 10.2 88.3 ± 9.5 NS
Mean ± SD body mass index (kg/m2) 32.1 ± 7.2 34.5 ± 6.3 NS
Impaired glucose tolerance (n) 19 17 NS
Type 2 diabetics (n) 1 3 NS
Metabolic syndrome components (n)a
31 1 1 0 N S
47 8 N S
52 2 N S
Total cholesterol (mg/dl) 212.6 ± 45.8 209.6 ± 50.8 NS
Low-density lipoprotein cholesterol (mg/dl) 134 ± 44 138 ± 34 NS
High-density lipoprotein cholesterol (mg/dl) 51.2 ± 11 56.3 ± 17 NS
Triglycerides (mg/dl) 221 ± 32 210 ± 23 NS
a Based on World Health Organization criteria [1].
Table 2: Mean ± SD metabolic parameters at baseline and end of treatment
Baseline p value End of treatment p value
Losartan Telmisartan Losartan Telmisartan
HOMA-IR 5.78 ± 3.53 5.74 ± 3.35 NS 5.82 ± 2.66 4.24 ± 2.36 < 0.05
FPG 110.05 ± 14.56 109.08 ± 16.67 NS 113.20 ± 12.68 100.00 ± 11.99 < 0.05
FPI 20.47 ± 9.64 18.86 ± 10.89 NS 20.14 ± 9.49 16.93 ± 8.91 < 0.06
2-hour OGTT 137.42 ± 32.5 131.31 ± 42.05 NS 134.6 ± 26.71 113.85 ± 42.14 < 0.01
HbA1c 6.27 ± 0.29 6.45 ± 0.35 NS 6.28 ± 0.21 5.85 ± 0.18 < 0.05Cardiovascular Diabetology 2005, 4:6 http://www.cardiab.com/content/4/1/6
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the abdomen at the level of iliac ridge at the end of a nor-
mal expiration, keeping the tape well tense, adhered to the
skin and parallel to the floor. Any adverse event was
recorded.
Data are presented as mean ± 1 SD or percentages when
appropriate. After testing data for normality, Wilcoxon
Signed Rank test was used to compare values before and
after each therapy and the relative changes in values in
response to each therapy. The effects of the losartan and
telmisartan on blood pressure and glucose metabolism
were analyzed by one way repeated measures analysis of
variance (ANOVA) or Friedman Repeated ANOVA on
Ranks. A p value <0.05 was considered statistically
significant.
Results
A total of 40 patients were enrolled, with 20 randomized
to each treatment group, baseline clinical characteristics
of study patients are shown in table 1, no significant dif-
ferences were noted between groups. All but four patients
had IGT, whereas one patient in the losartan group and
three in the telmisartan group had a diagnosis of type 2
diabetes.
Changes in metabolic parameters were observed at the
end of treatment compared with baseline (table 2). Com-
pared with losartan, telmisartan reduced FPG by 8% (p <
0.05), FPI by 10% (p < 0.06), HOMA-IR by 26% (p <
0.05) and HbA1c by 9% (p < 0.05) as shown in figure 1.
Losartan did not have a meaningful effect on these param-
eters. Levels of FPG and FPI following OGTT were also sig-
nificantly reduced by telmisartan compared with losartan
(figures 2 and 3).
After 3 months' treatment, telmisartan reduced 24-hour
mean SBP and DBP significantly more than losartan. The
superior blood pressure control with telmisartan was also
apparent when changes in mean daytime SBP (13.5 ± 0.8
vs 10.0 ± 1.1 mmHg; p < 0.05) and DBP (8.9 ± 0.6 vs 5.6
± 0.8 mmHg; p = 0.04) and mean night-time SBP (8.7 ±
0.9 vs 5.6 ± 1.3 mmHg; p < 0.05) and DBP (7.8 ± 1.1 vs
4.7 ± 0.8 mmHg; p < 0.05) were compared. There was no
significant correlation between the decrease in blood pres-
sure and the change in FPG (r = 0.28; p = 0.020) or FPI (r
= 0.036; p = 0.012). Telmisartan also improved the SBP
and DBP smoothness indices (figure 3).
Both telmisartan and losartan were well tolerated, with no
adverse events reported.
Discussion
This study found that, compared with once-daily losartan
50 mg, once-daily telmisartan 80 mg reduced 24-hour
mean blood pressure and blood pressure variability, and
improved glucose tolerance and insulin sensitivity.
Improvements were found in all three indices of glucose
and insulin metabolism- FPG, OGTT and HbA1c suggest-
ing that Telmisartan may be effective in reducing the pro-
gression of metabolic syndrome.
Losartan is an ARB that has been shown in the Losartan
Intervention For Endpoint reduction in hypertension
(LIFE) to reduce new-onset diabetes compared with aten-
olol [15]. However, β -blocker therapy is a risk factor for
the development of diabetes [16,17], so the hyperglyc-
emic effect of atenolol may explain this result. Telmisar-
tan is an ARB with a longer duration of action than
losartan [18]. Given once daily, telmisartan 80 mg signif-
icantly reduced 24-hour blood pressure compared with
losartan 50 mg, with especially large benefit in the last 6
hours of the dosing interval [18].
There is also clinical evidence that telmisartan has favour-
able metabolic effects. Previous studies showed that tel-
misartan 80 mg, but not valsartan 160 mg has an insulin-
sensitizing effect [19]. A 1-year study in patients with type
2 diabetes treated with telmisartan or eprosartan found
that only telmisartan improved plasma lipid profiles [20],
but did not significantly affect glycemia or insulin sensi-
tivity. However, a relatively low dose of telmisartan (40
mg once daily) was used in that study and, since telmisar-
tan acts as a partial PPARγ  agonist, this may have been
insufficient for a full manifestation of any hypoglycemic
effects. Telmisartan has been shown to improve plasma
total cholesterol and low-density lipoprotein (LDL)
Effect of telmisartan and losartan on measures of glycaemia  and insulin resistance in 40 patients with metabolic syndrome Figure 1
Effect of telmisartan and losartan on measures of glycaemia 
and insulin resistance in 40 patients with metabolic syn-
drome. FPG = fasting plasma glucose, FPI = fasting plasma 
insulin, HOMA-IR = homeostatic model assessment – insulin 
resistance, HbA1c = glycosylated haemoglobin.Cardiovascular Diabetology 2005, 4:6 http://www.cardiab.com/content/4/1/6
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cholesterol compared with nifedipine gastrointestinal
therapeutic system in patients with type 2 diabetes and
mild hypertension [21]. Furthermore, in a German sur-
veillance study of hypertensive patients receiving telmisar-
tan, the patients with type 2 diabetes had substantially
reduced plasma glucose and serum triglyceride concentra-
tions after 6 months' treatment [22].
FPG is the standard test used to diagnose Type 2 diabetes,
but it is also a marker for cardiovascular disease in its own
right [23]. Non-diabetic individuals with an FPG ≥  100
mg/dl (≥  5.6 mmol/l) but <126 mg/dl (<7.0 mmol/l) are
considered to have impaired fasting glucose and are at
increased risk of cardiovascular complications [24]. The
physiologic basis of the response to OGTT differs from
that of impaired FPG, with postprandial hyperglycemia
closely linked to a blunting of early-phase insulin release
[25]. It is often one of the earliest abnormalities that can
be detected in clinical practice (although OGTT is not rec-
ommended for routine clinical use). HbA1c provides an
index of plasma glucose concentrations during the previ-
ous 2–3 months [26]. It reflects both fasting and post-
prandial plasma glucose and, therefore, represents an
independent parameter [27]. In patients such as ours,
Effect of telmisartan and losartan during the OGTT in patients with metabolic syndrome Figure 2
Effect of telmisartan and losartan during the OGTT in patients with metabolic syndrome. A) Plasma glucose at baseline. B) 
Plasma glucose at endpoint. C) Plasma insulin at baseline. D) Plasma insulin at endpoint.Cardiovascular Diabetology 2005, 4:6 http://www.cardiab.com/content/4/1/6
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with high-normal levels of HbA1c, it is more closely
related to postprandial plasma glucose than to fasting val-
ues [27,28].
In addition to these measures of glycemia, this study also
used the HOMA-IR index, a measure of insulin resistance
derived from fasting levels of glucose and insulin and a
physiologically-based model [29], which is an effective,
easily-derived surrogate for the more complex euglycemic
clamp [30]. HOMA-IR was predictive of future diabetes in
the Mexico City Diabetes Study [31]. The reduction of
HOMA-IR seen in our study may, therefore, reduce the
progression from metabolic syndrome, although this has
not been studied experimentally.
In this study, losartan had no effect on measures of glyc-
emia or on HOMA-IR; a result that may seem surprising
given that losartan reduced the incidence of new-onset
diabetes in LIFE [15]. However, a previous study in hyper-
insulinemic, hypertensive patients found no effect on
insulin sensitivity or glucose tolerance following 12
weeks' treatment with either losartan or metoprolol [32].
This supports our finding that losartan is metabolically
neutral, but leaves open the question of whether the
results of LIFE were due to a pro-diabetogenic effect of
atenolol. They also support previous studies which sug-
gest that the PPARγ  agonism exhibited by telmisartan in
preclinical studies [10-12] has meaningful effects at the
clinical level.
There have been relatively few studies of PPARγ  agonists
in patients without diabetes. In one study, 24 hyperten-
sive, non-diabetic patients (mean BMI of 30 kg/m2) were
given rosiglitazone in addition to non-ACE inhibitor anti-
hypertensive therapy for 12 weeks. The result was a reduc-
tion in FPI (but not FPG) and an increase in glucose
disposal (measured using euglycemic clamp) [33]. In an
8-week, placebo-controlled study, 50 non-diabetic
patients who met a modified National Cholesterol Educa-
tion Program definition for the metabolic syndrome were
randomized to receive either rosiglitazone 4 mg/day or
placebo for 8 weeks. In these patients, rosiglitazone
reduced FPI by 40% and HOMA-IR by 45% compared
with placebo [34]. The magnitude of the sensitizing effect
with rosiglitazone was somewhat greater than that
observed with telmisartan in our study. Although these
difference may be a function of the differing population
and study protocol, they may also relate to the in vitro
observations that telmisartan is a selective PPARγ  modula-
tor (SPPARM) [10]. SPPARMs activate only a subset of
genes targeted by full PPARγ  agonists [35] and they may,
in particular, have a better adverse event profile. For this
reason, it is notable that telmisartan was well tolerated in
our study as in previous ones, with none of the peripheral
oedema and fluid retention that are characteristic of full
PPARγ  agonists [36].
As expected, both telmisartan and losartan reduced blood
pressure in our patients; however, reductions in 24-hour
mean SBP and DBP were significantly greater with tel-
misartan. A superior reduction in 24-hour mean SBP and
DBP with telmisartan 80 mg compared with losartan 50
mg has been found in a meta-analysis of previous studies,
partly due to telmisartan's longer duration of action [18].
The greater improvement in the smoothness index with
telmisartan compared with losartan is also significant,
given that this is an independent prognostic marker for
cardiovascular events [37].
Compared to other AT(1) receptor blockers telmisartan
may have further additional beneficial effects in patients
with the metabolic syndrome as suggested by this study
and by a recent report of Zhang et al that have shown that
that AT(1) receptor-mediated coronary constriction that is
augmented in the prediabetic metabolic syndrome and
contributes to impaired control of coronary blood flow is
beneficially affected by telmisartan[38].
Conclusion
This study found that telmisartan, but not losartan,
improves metabolic parameters in patients with meta-
bolic syndrome. Although treatment conventionally
Effect of telmisartan and losartan on the smoothness index at  endpoint Figure 3
Effect of telmisartan and losartan on the smoothness index at 
endpoint.Cardiovascular Diabetology 2005, 4:6 http://www.cardiab.com/content/4/1/6
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focuses on each risk factor individually, multifactorial
intervention reduces significantly the incidence of cardio-
vascular disease in type 2 diabetics with
microalbuminuria. The multifactorial effects of telmisar-
tan shown in this study could, therefore, provide synergis-
tic benefits in patients with hypertension and other
cardiovascular risk factors, such as glucose intolerance.
Such a provocative hypothesis will require confirmation
in large clinical trials, such as the ONgoing Telmisartan
Alone and in combination with Ramipril Global End-
point Trial (ONTARGET) [39].
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